138629-30-8

Usage

Uses

Used in Pharmaceutical Industry:
(2R)-2-[[[(1,1-DIMETHYLETHYL)DIPHENYLSILYL]OXY]METHYL]-5-OXO-1-PYRROLIDINECARBOXYLATE-1,1-DIMETHYLETHYL ESTER is used as a pharmaceutical intermediate for the synthesis of various drugs due to its complex structure and functional groups. Its lipophilic nature allows for improved drug delivery and bioavailability.
Used in Materials Industry:
In the materials industry, (2R)-2-[[[(1,1-DIMETHYLETHYL)DIPHENYLSILYL]OXY]METHYL]-5-OXO-1-PYRROLIDINECARBOXYLATE-1,1-DIMETHYLETHYL ESTER is used as a component in the development of advanced materials, such as polymers or coatings, that require specific chemical properties conferred by its functional groups.
Used in Organic Synthesis:
(2R)-2-[[[(1,1-DIMETHYLETHYL)DIPHENYLSILYL]OXY]METHYL]-5-OXO-1-PYRROLIDINECARBOXYLATE-1,1-DIMETHYLETHYL ESTER serves as a reactant or building block in organic synthesis, where its unique structure and functional groups can be utilized to create novel compounds with specific properties.
Used as a Protectant in Sensitive Reactions:
The diphenylsilyl group present in (2R)-2-[[[(1,1-DIMETHYLETHYL)DIPHENYLSILYL]OXY]METHYL]-5-OXO-1-PYRROLIDINECARBOXYLATE-1,1-DIMETHYLETHYL ESTER allows it to be used as a protectant for sensitive functional groups during chemical reactions, preventing unwanted side reactions and improving the yield of desired products.

Upstream product

• 81658-25-5 2-hydroxymethyl-5-oxopyrrolidine-1-carboxylic acid tert-butyl ester 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 7149-65-7 ethyl (S)-pyroglutamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 17342-08-4 (S)-Pyroglutaminol 
• 34619-03-9 tert-butyldicarbonate 
• 138629-44-4 (R)-5-(tert-butyl-diphenyl-silanyloxymethyl)-pyrrolidin-2-one 
• 68766-96-1 ethyl (R)-2-pyrrolidone-5-carboxylate 
• 132974-83-5 (5S)-5-[[(tert-butyldiphenylsilyl)oxy]methyl]pyrrolidin-2-one 
• 6893-26-1 D-Glutamic acid 
• 64700-65-8 methyl (2R)-pyroglutamate 
• 66673-40-3 (R)-5-hydroxymethylpyrrolidin-2-one 
• 185303-86-0 N-(tert-butoxycarbonyl)-6,7-O-isopropylidene-2,3-dideoxy-L-arabinoheptono-1,4-lactam 
• 141393-87-5 4-<(tert-butoxycarbonyl)amino>-6,7-O-isopropylidene-2,3,4-trideoxy-L-arabino-hept-2-enonic acid 1,4-lactam 

Downstream Products

• 138871-68-8 [(S)-1-(tert-Butyl-diphenyl-silanyloxymethyl)-4-[1,3]dithian-2-yl-4-oxo-butyl]-carbamic acid tert-butyl ester 
• 197142-40-8 (3R,5S)-3-Allyl-5-(tert-butyl-diphenyl-silanyloxymethyl)-2-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 494836-25-8 5-(tert-butyl-diphenyl-silanyloxymethyl)-3-ethyl-2-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 852674-76-1 [1-(tert-butyl-diphenyl-silanyloxymethyl)-9-(2-methyl-[1,3]dioxolan-2-yl)-4-oxo-nonyl]-carbamic acid tert-butyl ester 
• 885685-93-8 5-(tert-butyl-diphenyl-silanyloxymethyl)-3-[hydroxy-(2-methoxy-phenyl)-methyl]-2-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1000358-48-4 C₃₅H₅₅Si₂NO₆ 
• 885685-90-5 C₂₈H₃₁NO₃Si 
• 917600-42-1 C₂₈H₃₁NO₃Si 
• 885685-87-0 (3R,5S)-3-Bromo-5-(tert-butyl-diphenyl-silanyloxymethyl)-3-(2-methoxy-benzyl)-pyrrolidin-2-one 
• 885685-88-1 (3S,5S)-3-Bromo-5-(tert-butyl-diphenyl-silanyloxymethyl)-3-(2-methoxy-benzyl)-pyrrolidin-2-one 
• 885685-89-2 (3R,5S)-3-Bromo-5-(tert-butyl-diphenyl-silanyloxymethyl)-3-(2-hydroxy-benzyl)-pyrrolidin-2-one 
• 917600-39-6 (3S,5S)-3-Bromo-5-(tert-butyl-diphenyl-silanyloxymethyl)-3-(2-hydroxy-benzyl)-pyrrolidin-2-one 

Relevant academic research and scientific papers

COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS

The invention relates to a compound represented by Formula (I): or a pharmaceutically acceptable salt thereof, compositions comprising the same and methods of preparing and using the same. The variables are described herein.

Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression

A series of chemical optimizations guided by in vitro affinity at the α4β2 receptor in combination with selectivity against the α3β4 receptor, pharmacokinetic evaluation, and in vivo efficacy in a forced swim test resulted in identification of 3-(6-chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane hydrochloride (9h, SUVN-911) as a clinical candidate. Compound 9h is a potent α4β2 receptor ligand with a Ki value of 1.5 nM. It showed >10 μM binding affinity toward the ganglionic α3β4 receptor apart from showing selectivity over 70 other targets. It is orally bioavailable and showed good brain penetration in rats. Marked antidepressant activity and dose-dependent receptor occupancy in rats support its potential therapeutic utility in the treatment of depression. It does not affect the locomotor activity at doses several folds higher than its efficacy dose. It is devoid of cardiovascular and gastrointestinal side effects. Successful long-term safety studies in animals and phase-1 evaluation in healthy humans for safety, tolerability, and pharmacokinetics paved the way for its further development.

A Unified Strategy for the Synthesis of Difluoromethyl- And Vinylfluoride-Containing Scaffolds

Here, we report a general method for the synthesis of quaternary and tertiary difluoromethylated compounds and their vinylfluoride analogues. The strategy, which relies on a two-step sequence featuring a C-selective electrophilic difluoromethylation and either a palladium-catalyzed decarboxylative protonation or a Krapcho decarboxylation, is practical, scalable, and high yielding. Considering the generality of the method and the attractive properties offered by the difluoromethyl group, this approach provides a valuable tool for late-stage functionalization and drug development.

BACTERIAL EFFLUX PUMP INHIBITORS

Disclosed herein are compounds of formula I and salts thereof. Also disclosed are compositions comprising compounds of formula I and methods using compounds of formula I.

INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS

Disclosed herein are compounds of formula (I): and salts thereof. Also disclosed are compositions comprising compounds of formula I and compounds of formula I for use in treating or preventing bacterial infections.

BACTERIAL EFFLUX PUMP INHIBITORS

Disclosed herein are compounds of formula I: and salts thereof. Also disclosed are compositions comprising compounds of formula I and methods using compounds of formula I.

CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

There is described a novel group of cyclic amine derivative compounds, having an EP4 receptor antagonistic activity and specifically pharmaceutical compounds which are useful for the treatment or alleviation of Prostaglandin E mediated diseases. The present invention therefore relates to novel compounds which are selective antagonists of the EP4 subtype of PGE2 receptors with analgesic and antinflammatory activity, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, migraine and endometriosis.

SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS

The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Structural Properties and Stereochemically Distinct Folding Preferences of 4,5-cis and trans-Methano- L -Proline Oligomers: The Shortest Crystalline PPII-Type Helical Proline-Derived Tetramer

The synthesis, structural properties, and folding patterns of a series of L-proline methanologues represented by cis- and trans-4,5-methano-L-proline amides and their oligomers are reported as revealed by X-ray crystallography, circular dichroism measurements, and DFT calculations. We disclose the first example of a crystalline tetrameric proline congener to exhibit a polyproline II helical conformation. Experimental evidence of PPII-type helical arrangement (both in solution and in the solid state) of cis-4,5-methano-L-proline oligomers is supported by theoretical calculations reflecting the extent of n→π? stabilization of the trans-amide conformation.

Methanesulfonic acid mediated cyclization and meyer-schuster rearrangement of γ-amino-ynones: Access to enantiopure pyrrolidine exocyclic vinylogous amides

α- and β-Amino-ynones have been largely used to prepare heterocyclic rings in the presence of various electrophiles such as protic acids or gold(I). Herein we disclose the unprecedented formation of pyrrolidine exocyclic vinylogous amides, in place of the expected azepinones or piperidinones, starting from γ-amino-ynones derived from amino acids. The process involves a tandem 1,2-addition of the protected nitrogen to the carbonyl group followed by a Meyer-Schuster rearrangement, which efficiently afforded enantiopure pyrrolidine exocyclic vinylogous amides. The sequence is poorly catalyzed by gold salts, but proved to be very efficient in the presence of methanesulfonic acid. Copyright